{
    "id": 6396,
    "fullName": "SMO F460L",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "SMO F460L lies within transmembrane domain 6 in the Smo protein (UniProt.org). F460L is predicted to confer a gain of function to the Smo protein as demonstrated by ligand-independent activation of Hedgehog signaling in cell culture and has also been demonstrated to confer resistance to Hedgehog pathway inhibitors (PMID: 25759020).",
            "references": [
                {
                    "id": 2677,
                    "pubMedId": 25759020,
                    "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759020"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 6608,
        "geneSymbol": "SMO",
        "terms": [
            "SMO",
            "CRJS",
            "FZD11",
            "Gx",
            "SMOH"
        ]
    },
    "variant": "F460L",
    "createDate": "05/18/2015",
    "updateDate": "09/23/2019",
    "referenceTranscriptCoordinates": {
        "id": 123182,
        "transcript": "NM_005631",
        "gDna": "chr7:g.129209309T>C",
        "cDna": "c.1378T>C",
        "protein": "p.F460L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2195,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a transformed cell line expressing SMO F460L demonstrated resistance to Erivedge (vismodegib) as compared to wild-type (PMID: 25759020).",
            "molecularProfile": {
                "id": 6246,
                "profileName": "SMO F460L"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2677,
                    "pubMedId": 25759020,
                    "title": "Smoothened variants explain the majority of drug resistance in basal cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25759020"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6246,
            "profileName": "SMO F460L",
            "profileTreatmentApproaches": [
                {
                    "id": 18444,
                    "name": "GLI1/2 inhibitor",
                    "profileName": "SMO F460L"
                },
                {
                    "id": 18443,
                    "name": "SMO Inhibitor",
                    "profileName": "SMO F460L"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123182,
            "transcript": "NM_005631",
            "gDna": "chr7:g.129209309T>C",
            "cDna": "c.1378T>C",
            "protein": "p.F460L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}